share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:拟议出售证券
美股sec公告 ·  07/10 13:04
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 50,000 Class A shares on 07/10/2024, with an aggregate market value of $374,000. These shares were originally acquired on 09/01/2016 as founders shares and were part of Gibson's compensation from the issuer. This planned sale follows a recent history of transactions where a total of 200,000 shares were sold over the past three months, generating gross proceeds of $1,681,000.
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 50,000 Class A shares on 07/10/2024, with an aggregate market value of $374,000. These shares were originally acquired on 09/01/2016 as founders shares and were part of Gibson's compensation from the issuer. This planned sale follows a recent history of transactions where a total of 200,000 shares were sold over the past three months, generating gross proceeds of $1,681,000.
Recursion Pharmaceuticals, Inc.官员和董事Christopher Gibson计划在07/10/2024出售50,000股A类股票,市场总价值为$374,000。这些股票最初是在2016年9月1日以创始人的身份获得的,并且是Gibson从发行人获得的报酬的一部分。此次计划出售是在过去三个月内进行的总计200,000股股票交易的基础上成立的,合计获得1,681,000美元的总收入。
Recursion Pharmaceuticals, Inc.官员和董事Christopher Gibson计划在07/10/2024出售50,000股A类股票,市场总价值为$374,000。这些股票最初是在2016年9月1日以创始人的身份获得的,并且是Gibson从发行人获得的报酬的一部分。此次计划出售是在过去三个月内进行的总计200,000股股票交易的基础上成立的,合计获得1,681,000美元的总收入。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息